| L - Antineoplastic and Immunomodulating Agents | This group comprises preparations used in the treatment of neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.
|
|
| L03 - Immunostimulants | Immunosuppressants, see L04A.
|
|
| L03A - Immunostimulants | Levamisole, which also affects the immune response, is classified in P02CE.
|
|
| L03AA - Colony Stimulating Factors | | | The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.
|
|
| L03AA13 - Pegfilgrastim | | Dose | Route of administration | Note |
|---|
| | P | |
|
|
